An at-home flu vaccine? If approved, it could open the door to more DIY options

A new way to administer vaccines at home could help AstraZeneca reach a wider market for FluMist, the nasal influenza vaccine.

By Kelly Bilodeau • Nov. 8, 2023

23andMe CEO Anne Wojcicki’s vision for changing healthcare as a ‘full-fledged biotech’

23andMe always had bigger aims than at-home genetics testing. In this in-depth interview, the company’s founder explains its foray into pharma, drug R&D, solving cold cases and more.  

By Alexandra Pecci • Nov. 7, 2023

Explore the Trendline➔

Clinical trial diversity

As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.

By PharmaVoice staff

The thorniest questions facing pharma, according to a leading bioethicist

Bioethics guru Arthur Caplan of NYU gives his outspoken and frank opinion on the industry’s minefield of ethical challenges.

By Michael Gibney • Nov. 6, 2023

PharmaVoice 100s: Entrepreneurs

From biotech startups to a services agency, these entrepreneurs are hedging their bets to offer innovative approaches in patient care.

By Meagan Parrish • Nov. 3, 2023

Wisp’s ‘bold and unapologetic approach’ to women’s sexual and reproductive health

In the role of interim CEO of Wisp, Monica Cepak aims to break down barriers and expand access via telehealth.

By Alexandra Pecci • Oct. 31, 2023

Red Jacket: Adele Gulfo, a commercialization guru

With a knack for melding science and patient-focused marketing techniques, the CEO of the biopharma commercial unit at Sumitomo Pharma America has notched blockbuster successes throughout her career.

By Karissa Waddick • Oct. 27, 2023

Red Jacket: Helen Sabzevari, an immunotherapy pioneer

Precigen’s CEO is pushing for her next therapeutic breakthrough with innovative cell and gene therapy platforms.

By Meagan Parrish • Oct. 27, 2023

The 2023 Red Jacket honorees

This year's inductees to the PharmaVoice 100 "hall of fame" are leaders who have been at the forefront — and will stay at the forefront — of industry change.

By Meagan Parrish • Oct. 27, 2023

Patient groups have become a powerhouse in R&D. Here’s a look at their impact.

“They have the money,” and they’re using it to influence drug development, according to the executive director of the IQVIA Institute for Human Data Science.

By Kelly Bilodeau • Oct. 25, 2023

Actor and epilepsy advocate Greg Grunberg wants the world to ‘talk about it’

The actor of “Heroes” and “Star Wars: The Force Awakens” fame is starring in another role as a patient advocate for people with epilepsy.

By Michael Gibney • Oct. 19, 2023

From the rainforest to Wall Street — Jaguar Health’s big play for revitalization

A pharma with a massive collection of rainforest-derived plants needs a regulatory win to overcome last year’s financial decline.

By Kelly Bilodeau • Oct. 17, 2023

PharmaVoice 100s: Rare disease warriors

Biopharma leaders pounding away at rare diseases so patients with few other options can have healthier lives.

By Michael Gibney • Oct. 16, 2023

PharmaVoice 100s: Patient heroes

Leaders innovating new ways to incorporate patient voices in drug development and decrease barriers to access. 

By Karissa Waddick • Oct. 13, 2023

Branded: The trademarks pharma leaders look up to

What do brands like Patagonia, Nike and Lego have to do with pharma? Here are some of the brands industry leaders relate to most — and how they inspire work in the life sciences.

By PharmaVoice Staff • Oct. 13, 2023

A decade later, biotech’s CRISPR revolution is still going strong

Once the specialty of a few select drugmakers, CRISPR gene editing is now an essential technology for a growing group of biotechs, many led by former students of the field's pioneering scientists.

By Gwendolyn Wu , Shaun Lucas , Julia Himmel • Oct. 12, 2023

To close the pediatric innovation gap, this biotech has to think differently

Day One Biopharmaceuticals is bucking the cancer drug development trend by working with children and adults simultaneously.

By Alexandra Pecci • Oct. 11, 2023

3 recent FDA adcomm rejections — and why they matter

Decisions that could spell doom for drugs in development and already on the shelves.

By Meagan Parrish • Sept. 29, 2023

Do humans have a place in pharma’s AI future?

From COTA’s large datasets and AI model assistants to a company guiding patients through cancer care, AI can help — but it’s a long way from human-free.

By Michael Gibney • Sept. 26, 2023

Elderly exclusion: Clinical trials still fall short enrolling older adults

Despite high rates of disease in older populations, systemic issues are keeping them out of research studies.

By Kelly Bilodeau • Sept. 25, 2023

Optimizing your hub services program with a gross-to-net lens

In today’s Biopharma landscape, considering Gross-to-Net is essential for effectively designing and optimizing patient support programs.

Sept. 25, 2023

Three years after an FDA rejection, DBV sees a path for its peanut patch

Despite lower-than-expected demand for a competing treatment, DBV’s chief medical officer says the company’s topical skin patch could be a game-changing option for patients.

By Karissa Waddick • Sept. 22, 2023

As the opioid crisis seethes, a long-lasting treatment could offer new ammunition

Launched this month, Brixadi from Braeburn gives patients a new tool to overcome addiction.

By Michael Gibney • Sept. 21, 2023

What happened to ivermectin?

The saga of the anti-parasitic drug continues.

By Alexandra Pecci • Sept. 20, 2023

The 2023 PharmaVoice 100

This year’s honorees are influential and devoted leaders lifting the pillars of the industry to new heights.

By Julia Himmel • Sept. 19, 2023

O.G. Ice-T teams up with Sanofi in horror-themed flu vax ad

The French pharma’s latest vaccine campaign aims to raise awareness about the flu’s complications for marginalized groups. 

By Karissa Waddick • Sept. 14, 2023